Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 392

1.

Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: A prospective cohort study.

Højgaard P, Ellegaard K, Nielsen SM, Christensen R, Guldberg-Møller J, Ballegaard C, Dreyer L, Mease P, de Wit M, Skov L, Glintborg B, Bliddal H, Bartels EM, Amris K, Kristensen LE.

Arthritis Care Res (Hoboken). 2018 Jul 5. doi: 10.1002/acr.23693. [Epub ahead of print]

PMID:
29975012
2.

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Palmer JB, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, Karki C, Greenberg JD.

J Rheumatol. 2018 Jul 1. pii: jrheum.171094. doi: 10.3899/jrheum.171094. [Epub ahead of print]

3.

Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study.

Landewé R, Sieper J, Mease P, Inman RD, Lambert RG, Deodhar A, Marzo-Ortega H, Magrey M, Kiltz U, Wang X, Li M, Zhong S, Mostafa NM, Lertratanakul A, Pangan AL, Anderson JK.

Lancet. 2018 Jun 28. pii: S0140-6736(18)31362-X. doi: 10.1016/S0140-6736(18)31362-X. [Epub ahead of print]

PMID:
29961640
4.

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD.

Rheumatology (Oxford). 2018 Jun 25. doi: 10.1093/rheumatology/key161. [Epub ahead of print]

PMID:
29945203
5.

Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study.

Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Scarpa R, Marchesoni A, Taylor WJ, Salvarani C, Kalden J, Lubrano E, Carneiro S, Piga M, Floris A, Desiati F, Flynn JA, D'Angelo S, van Kuijk AWR, Catanoso MG, Caso F, Contu P, Ujfalussy I, Helliwell PS, Mease PJ; for the GRAPPA 3PPsA Study Group.

J Rheumatol. 2018 Jun 15. pii: jrheum.171183. doi: 10.3899/jrheum.171183. [Epub ahead of print]

PMID:
29907666
6.

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.

McInnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, Pricop L, Jugl SM, Gandhi KK; FUTURE 2 Study Group.

Arthritis Res Ther. 2018 Jun 7;20(1):113. doi: 10.1186/s13075-018-1610-3.

7.

Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

Nash P, McInnes IB, Mease PJ, Thom H, Hunger M, Karabis A, Gandhi K, Mpofu S, Jugl SM.

Rheumatol Ther. 2018 Jun 1. doi: 10.1007/s40744-018-0117-3. [Epub ahead of print]

8.

GRAPPA 2017 Project Report.

Callis Duffin K, FitzGerald O, Kavanaugh A, Mease PJ, Merola JF, Ogdie A, O'Sullivan D, Reddy SM, Ritchlin CT, Coates LC.

J Rheumatol Suppl. 2018 Jun;94:48-51. doi: 10.3899/jrheum.180139.

PMID:
29858355
9.

The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database.

Gladman DD, Coates LC, Jadon DR, Tillett W, Mease PJ, Vis M.

J Rheumatol Suppl. 2018 Jun;94:26-29. doi: 10.3899/jrheum.180132.

PMID:
29858349
10.

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

Holland R, Tillett W, Ogdie A, Leung YY, Gladman DD, Callis Duffin K, Coates LC, Mease PJ, Eder L, Strand V, Elmamoun M, Højgaard P, Chau J, de Wit M, Goel N, Lindsay CA, FitzGerald O, Shea B, Beaton D, Orbai AM.

J Rheumatol Suppl. 2018 Jun;94:17-25. doi: 10.3899/jrheum.180142.

PMID:
29858348
11.

Phase 2 Study of ABT-122, a TNF- and IL-17A-Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis With Inadequate Methotrexate Response.

Mease PJ, Genovese MC, Weinblatt ME, Peloso PM, Chen K, Othman AA, Li Y, Mansikka HT, Khatri A, Wishart N, Liu J.

Arthritis Rheumatol. 2018 May 31. doi: 10.1002/art.40579. [Epub ahead of print]

PMID:
29855175
12.

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin CT, Huynh DH, Palmer JB, Greenberg JD.

RMD Open. 2018 Apr 25;4(1):e000638. doi: 10.1136/rmdopen-2017-000638. eCollection 2018.

13.

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

Nash P, McInnes IB, Mease PJ, Thom H, Hunger M, Karabis A, Gandhi K, Mpofu S, Jugl SM.

Rheumatol Ther. 2018 Jun;5(1):99-122. doi: 10.1007/s40744-018-0106-6. Epub 2018 Mar 31. Erratum in: Rheumatol Ther. 2018 Jun 1;:.

14.

Considerations for the definition of remission criteria in psoriatic arthritis.

Mease PJ, Coates LC.

Semin Arthritis Rheum. 2018 Jun;47(6):786-796. doi: 10.1016/j.semarthrit.2017.10.021. Epub 2017 Oct 31. Review.

15.

The Effect of Psoriatic Arthritis on Ixekizumab Clinical Outcomes in Moderate-to-Severe Psoriasis Patients: A Post Hoc Analysis.

Gottlieb AB, Papp KA, Birbara CA, Shuler CL, Burge R, Erickson J, Kerr L, Mease PJ.

J Am Acad Dermatol. 2018 Mar 17. pii: S0190-9622(18)30458-4. doi: 10.1016/j.jaad.2018.03.008. [Epub ahead of print] No abstract available.

PMID:
29559395
16.

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.

van der Heijde D, Deodhar A, FitzGerald O, Fleischmann R, Gladman D, Gottlieb AB, Hoepken B, Bauer L, Irvin-Sellers O, Khraishi M, Peterson L, Turkiewicz A, Wollenhaupt J, Mease PJ.

RMD Open. 2018 Mar 14;4(1):e000582. doi: 10.1136/rmdopen-2017-000582. eCollection 2018. Erratum in: RMD Open. 2018 Mar 26;4(1):.

17.

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.

Mease P, van der Heijde D, Landewé R, Mpofu S, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Meiser K, Readie A, Pricop L, Abrams K.

Ann Rheum Dis. 2018 Jun;77(6):890-897. doi: 10.1136/annrheumdis-2017-212687. Epub 2018 Mar 17.

18.

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).

Nash P, Mease PJ, McInnes IB, Rahman P, Ritchlin CT, Blanco R, Dokoupilova E, Andersson M, Kajekar R, Mpofu S, Pricop L; FUTURE 3 study group.

Arthritis Res Ther. 2018 Mar 15;20(1):47. doi: 10.1186/s13075-018-1551-x.

19.

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA).

Mease PJ, Gladman DD, Samad AS, Coates LC, Liu LXH, Aras GA, Collier DH, Chung JB.

RMD Open. 2018 Feb 3;4(1):e000606. doi: 10.1136/rmdopen-2017-000606. eCollection 2018.

20.

Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2.

Van den Bosch F, Mease PJ, Sieper J, Baeten DL, Xia Y, Chen S, Pangan AL, Song IH.

RMD Open. 2018 Feb 26;4(1):e000566. doi: 10.1136/rmdopen-2017-000566. eCollection 2018.

21.

Tofacitinib for Psoriatic Arthritis.

Mease P, Gladman D.

N Engl J Med. 2018 Feb 22;378(8):775-776. doi: 10.1056/NEJMc1715189. No abstract available.

22.

Real-world burden of comorbidities in US patients with psoriatic arthritis.

Shah K, Paris M, Mellars L, Changolkar A, Mease PJ.

RMD Open. 2017 Dec 28;3(2):e000588. doi: 10.1136/rmdopen-2017-000588. eCollection 2017.

23.

Anti-Inflammatory Effects of Intra-Articular Hyaluronic Acid: A Systematic Review.

Altman R, Bedi A, Manjoo A, Niazi F, Shaw P, Mease P.

Cartilage. 2018 Feb 1:1947603517749919. doi: 10.1177/1947603517749919. [Epub ahead of print]

PMID:
29429372
24.

Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study.

Coates LC, Mease PJ, Gossec L, Kirkham B, Sherif B, Gaillez C, Mpofu S, Jugl SM, Karyekar C, Gandhi KK.

Arthritis Care Res (Hoboken). 2018 Feb 6. doi: 10.1002/acr.23537. [Epub ahead of print]

PMID:
29409133
25.

Characterization of Patients With Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in the US-Based Corrona Registry.

Mease PJ, van der Heijde D, Karki C, Palmer JB, Liu M, Pandurengan R, Park Y, Greenberg JD.

Arthritis Care Res (Hoboken). 2018 Feb 6. doi: 10.1002/acr.23534. [Epub ahead of print]

PMID:
29409123
26.

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.

Coates LC, Kishimoto M, Gottlieb A, Shuler CL, Lin CY, Lee CH, Mease PJ.

RMD Open. 2017 Dec 22;3(2):e000567. doi: 10.1136/rmdopen-2017-000567. eCollection 2017.

27.

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).

van der Heijde D, Gladman DD, Kishimoto M, Okada M, Rathmann SS, Moriarty SR, Shuler CL, Carlier H, Benichou O, Mease PJ.

J Rheumatol. 2018 Mar;45(3):367-377. doi: 10.3899/jrheum.170429. Epub 2017 Dec 15.

28.

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial.

Mease PJ, Kavanaugh A, Coates LC, McInnes IB, Hojnik M, Zhang Y, Anderson JK, Dorr AP, Gladman DD.

RMD Open. 2017 Jul 18;3(1):e000415. doi: 10.1136/rmdopen-2016-000415. eCollection 2017.

29.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS.

Arthritis Rheumatol. 2018 Mar;70(3):345-355. doi: 10.1002/art.40391. Epub 2018 Feb 6.

PMID:
29193765
30.

CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study.

Mease PJ, Jeka S, Jaller JJ, Kitumnuaypong T, Louthrenoo W, Mann H, Matsievskaia G, Soriano ER, Jia B, Wang C, Nie J, Hsia E.

J Rheumatol. 2018 Jan;45(1):22-31. doi: 10.3899/jrheum.161238. Epub 2017 Nov 1.

31.

Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study.

Ballegaard C, Jørgensen TS, Skougaard M, Strand V, Mease PJ, Kristensen LE, Dreyer L, Gottlieb A, de Wit M, Christensen R, Tarp S.

Arthritis Care Res (Hoboken). 2017 Oct 26. doi: 10.1002/acr.23455. [Epub ahead of print]

PMID:
29073353
32.

Remission in psoriatic arthritis-where are we now?

Coates LC, Conaghan PG, D'Agostino MA, De Wit M, FitzGerald O, Kvien TK, Lories R, Mease P, Nash P, Schett G, Soriano ER, Emery P.

Rheumatology (Oxford). 2017 Oct 16. doi: 10.1093/rheumatology/kex344. [Epub ahead of print]

PMID:
29045698
33.

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.

Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS.

N Engl J Med. 2017 Oct 19;377(16):1537-1550. doi: 10.1056/NEJMoa1615975.

34.

A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative.

Højgaard P, Klokker L, Orbai AM, Holmsted K, Bartels EM, Leung YY, Goel N, de Wit M, Gladman DD, Mease P, Dreyer L, Kristensen LE, FitzGerald O, Tillett W, Gossec L, Helliwell P, Strand V, Ogdie A, Terwee CB, Christensen R.

Semin Arthritis Rheum. 2018 Apr;47(5):654-665. doi: 10.1016/j.semarthrit.2017.09.002. Epub 2017 Sep 9. Review.

PMID:
29037523
35.

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.

McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, Kajekar R, Delicha EM, Pricop L, Mpofu S.

Rheumatology (Oxford). 2017 Nov 1;56(11):1993-2003. doi: 10.1093/rheumatology/kex301.

36.

The unmet need in rheumatology: Reports from the targeted therapies meeting 2017.

Winthrop KL, Strand V, van der Heijde D, Mease P, Crow M, Weinblatt M, Bathon J, Burmester GR, Dougados M, Kay J, Mariette X, Van Vollenhoven R, Sieper J, Melchers F, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Clin Immunol. 2018 Jan;186:87-93. doi: 10.1016/j.clim.2017.08.009. Epub 2017 Aug 12.

PMID:
28811201
37.

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies.

Tillett W, Orbai AM, Ogdie A, Leung YY, Strand V, Gladman DD, Mease PJ, Coates LC; GRAPPA OMERACT Psoriatic Arthritis working group.

Ann Rheum Dis. 2018 May;77(5):e23. doi: 10.1136/annrheumdis-2017-212004. Epub 2017 Jul 26. No abstract available.

PMID:
28747326
38.

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D.

Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.

39.

Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study.

Brown MA, Bird PA, Robinson PC, Mease PJ, Bosch FVD, Surian C, Jones H, Szumski A, Marshall L, Wiid Z, Dougados M.

Ann Rheum Dis. 2018 Jul;77(7):1091-1093. doi: 10.1136/annrheumdis-2017-211313. Epub 2017 Jul 3. No abstract available.

PMID:
28673924
40.

Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry.

Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD.

J Rheumatol. 2017 Aug;44(8):1151-1158. doi: 10.3899/jrheum.160963. Epub 2017 Jun 15.

PMID:
28620063
41.

New pathways of treatment for psoriatic arthritis.

Mease P.

Lancet. 2017 Jun 10;389(10086):2268-2270. doi: 10.1016/S0140-6736(17)31427-7. Epub 2017 May 24. No abstract available.

PMID:
28551071
42.

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.

van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A.

Rheumatology (Oxford). 2017 Sep 1;56(9):1498-1509. doi: 10.1093/rheumatology/kex174.

43.

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.

Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD.

Ann Rheum Dis. 2017 Sep;76(9):1550-1558. doi: 10.1136/annrheumdis-2016-210724. Epub 2017 May 4.

44.

GRAPPA 2016 Project Report.

Helliwell PS, FitzGerald O, Coates LC, Callis Duffin K, Mease PJ.

J Rheumatol. 2017 May;44(5):706-710. doi: 10.3899/jrheum.170153.

PMID:
28461534
45.

Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group.

Ogdie A, de Wit M, Callis Duffin K, Campbell W, Chau J, Coates LC, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, James J, Kalyoncu U, Latella J, Lindsay C, Mease PJ, O'Sullivan D, Steinkoenig I, Strand V, Tillett W, Orbai AM.

J Rheumatol. 2017 May;44(5):697-700. doi: 10.3899/jrheum.170150.

46.

International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting.

Coates LC, Chandran V, Ogdie A, O'Sullivan D, Brooke M, Steinkoenig I, Mease PJ, Ritchlin CT, Kavanaugh A.

J Rheumatol. 2017 May;44(5):684-685. doi: 10.3899/jrheum.170144.

PMID:
28461525
47.

Proceedings of the GRAPPA 2016 Retreat.

Jadon DR, Gladman DD, Mease PJ, FitzGerald O, Chandran V, Goel N, Rosen CF, Maksymowych WP, Ritchlin CT, Ogdie A, Coates LC, Cauli A, Soriano ER, Husni ME, Campbell W, Azevedo VF, Callis Duffin K, Armstrong AW, Gottlieb AB, Kavanaugh A, Garg A, Helliwell PS.

J Rheumatol. 2017 May;44(5):668-673. doi: 10.3899/jrheum.170141.

PMID:
28461522
48.

Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment.

Mease PJ.

Curr Opin Rheumatol. 2017 Jul;29(4):304-310. doi: 10.1097/BOR.0000000000000388. Review.

PMID:
28394827
49.

Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD.

Arthritis Care Res (Hoboken). 2017 Nov;69(11):1692-1699. doi: 10.1002/acr.23249.

PMID:
28376239
50.

Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab.

Mease PJ, Van den Bosch F, Sieper J, Xia Y, Pangan AL, Song IH.

J Rheumatol. 2017 May;44(5):599-608. doi: 10.3899/jrheum.160387. Epub 2017 Mar 15.

Supplemental Content

Support Center